Scientists uncover a new approach for treating aggressive cancer
Researchers have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then designed a new small-molecule, MS177, based on the proteolysis-targeting chimera (PROTAC) technology, that targets both EZH2 and cMyc and thus inhibits cancer growth.
Materials provided by UNC Lineberger Comprehensive Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa